Julius Ho-Fai Wong

Chinese University of Hong Kong

Papers

2

Total Citations

7

H-Index

2

About

Dr. Julius Ho-Fai Wong is a pioneering urological surgeon and researcher whose work is reshaping the surgical management of urologic cancers. His primary research areas center on robotic-assisted surgery, lymphatic complications, and the development of novel transurethral platforms for bladder cancer treatment. Dr. Wong’s most significant contribution is his landmark randomized controlled trial demonstrating that Hemopatch effectively prevents lymphatic leak after robotic prostatectomy and pelvic lymph node dissection—a common and debilitating complication. This work, cited 4 times, provides a practical, evidence-based solution that directly improves patient recovery. More recently, Dr. Wong has broken new ground with the first phase of the VIABLE trial, introducing a novel transurethral robotic platform for en bloc resection of bladder tumors. With 3 citations, this early-phase study signals a potential paradigm shift in how bladder cancer is surgically addressed, moving toward less invasive, more precise tumor removal. Dr. Wong’s work is notable not only for its clinical impact but also for its forward-looking innovation, positioning him as a key figure in the evolution of minimally invasive urologic oncology.

Research Focus

Key Achievements

2
H-Index
2
Papers
7
Total Citations
4
Avg Citations/Paper
🏆 Most Cited Paper
Hemopatch to Prevent Lymphatic Leak after Robotic Prostatectomy and Pelvic Lymph Node Dissection: A Randomized Controlled Trial
4 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Chinese University of Hong Kong

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago